CVS vs GDRX
CVS: A leading health solutions company integrating retail pharmacy, pharmacy benefit management, and insurance services to manage health costs and improve access to care. GDRX: GoodRx is a leading digital healthcare platform helping consumers navigate the complexities of prescription drug pricing and access affordable care.
Side-by-side fundamentals
| Metric | CVS | GDRX | Edge |
|---|---|---|---|
| Price as of 2026-10-20 close | $94.75 | $3.52 | |
| Market cap | $121.2B | $1.2B | |
| P/E as of 2026-10-20 | 25.00 | 58.67 | CVS lower |
| Net margin FY2025, SEC XBRL | +0.4% | +3.8% | GDRX higher |
| Operating margin FY2025, SEC XBRL | +1.2% | +11.0% | GDRX higher |
| ROE FY2025, SEC XBRL | +2.4% | +4.9% | GDRX higher |
| ROA FY2025, SEC XBRL | +0.7% | +2.2% | GDRX higher |
| Debt / equity | 0.77 | 0.75 | GDRX lower |
| Revenue growth (YoY) FY2025, SEC XBRL | +7.8% | +0.6% | CVS higher |
| Revenue CAGR (3y) SEC XBRL | +7.6% | +1.3% | CVS higher |
| Dividend yield as of 2026-09-03 | +3.0% | n/a | |
| Dividend streak (yrs) SEC XBRL | 19 | 0 | CVS higher |
| Beta as of 2026-09-03 | 0.28 | 1.22 | |
| 1-year return as of 2026-10-20 close | +14.9% | -11.6% | CVS higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.